Literature DB >> 31949632

Composite angioimmunoblastic T cell/diffuse large B-cell lymphoma treated with reduced-intensity conditioning HLA-haploidentical allo-HSCT: a case report and review of the literature.

Ruimin Hong1, Lixia Sheng1, Guifang Ouyang1.   

Abstract

Cases of diffuse large B-cell lymphoma (DLBCL) occurring together with angioimmunoblastic T cell lymphoma (AITL) are rare. Treatments for AITL and DLBCL composite lymphoma include chemotherapy, targeted therapy, immunomodulatory therapy and hematopoietic stem cell transplantation, but no standard treatment for this aggressive disease has yet been defined. There are no case reports on AITL/DLBCL composite lymphoma treated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). Herein, we report a case of AITL/DLBCL composite lymphoma treated with reduced-intensity conditioning HLA-haploidentical allo-HSCT, and the patient still remains in complete remission (CR) after a year of regular follow-up. IJCEP
Copyright © 2018.

Entities:  

Keywords:  Angioimmunoblastic T cell lymphoma; allogeneic hematopoietic stem cell transplantation; composite lymphoma; diffuse large B-cell lymphoma

Year:  2018        PMID: 31949632

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  2 in total

Review 1.  Neoplasms of follicular helper T-cells: an insight into the pathobiology.

Authors:  Surabhi Jain; Saumyaranjan Mallick; Prashant Ramteke; Ajay Gogia
Journal:  Am J Blood Res       Date:  2022-06-20

2.  Promising Response to Lenalidomide-Combination Therapy in a Discordant Lymphoma Consisting of EBV-Positive Diffuse Large B-Cell Lymphoma and Angioimmunoblastic T-Cell Lymphoma: A Case Report.

Authors:  Pan Hu; Yu Ben; Juan Liu; Weicheng Zheng; Xiyue Yan; Yaping Zhang; Wenyu Shi
Journal:  Onco Targets Ther       Date:  2021-04-12       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.